Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 24 July 2008, doi:10.1136/bmj.a406
Cite this as: BMJ 2008;337:a406
May improve control of measles but is no substitute for doses given at 9-15 months
| The first 150 words of the full text of this article appear below. |
Before vaccination, measles was ubiquitous and caused many deaths in children under 5 years. Routine vaccination in high income countries since the 1960s has successfully controlled measles. In low income countries, measles vaccination was included in the World Health Organizations expanded immunisation programme since 1974. Interruption of measles transmission has been documented in most countries of the Americas,1 and the recent increase in vaccination coverage in Africa has been followed by an estimated 75% decline in annual mortality over the past decade. However, the disease remains an important and unacceptable cause of death in Africa and South Asia.
In the linked randomised controlled trial, Martins and colleagues assess the protective efficacy of vaccination at 4.5 months in infants during an outbreak in Guinea-Bissau.2 In most nations, vaccination strategies are based on the provision of a first dose at age 9-15 months and either a second scheduled dose or a subsequent
H Broutin, postdoctoral researcher 1, M A Miller, associate director for research 1
1 Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, MD 20892, USA
broutinh@mail.nih.gov
Israeli students are refusing to perform intimate examinations on anaesthetised women without their informed consent.